Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study.
Diabetic macular oedema
Intravitreal injection therapy
Macular degeneration
Optical coherence tomography
Retinal vein occlusion
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
22
11
2022
accepted:
31
01
2023
revised:
22
01
2023
medline:
26
7
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
To investigate the lower visual acuity threshold for recommending intravitreal injection therapy (IVI). The lower limit of 1.3 logMAR best-corrected visual acuity (BCVA) was adopted in 2006 and has been maintained since then. In this retrospective study, data from patients with a logMAR BCVA ≤ 1.3 and 24 months follow-up were analysed. We included patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), or retinal vein occlusion (RVO). The data from 164 patients (nAMD: 107; DME: 15; RVO: 42) were analysed. We observed a significant improvement at all time intervals (0 to 6, 6 to 12, 12 to 18, and 18 to 24 months after initiating IVI) compared to baseline. Across all indications, median BCVA improved from 1.4 to 1.0 within the first 6 months and remained stable within 24 months. Patients received a median of 5 and 10 injections within 6 and 24 months, respectively. Median foveal retinal thickness was 594.5 μm at baseline and dropped to 244.5 μm, 235.5 µm, 183 µm, and 180 µm during the four consecutive time intervals. Patients with nAMD, DME, and RVO with poor baseline BCVA may also benefit from intravitreal therapy with VEGF-inhibitors. In the present study, we observed functional and morphological improvement over 2 years irrespective of the underlying macular disease. Those patients should not be excluded from therapy.
Identifiants
pubmed: 36929056
doi: 10.1007/s00417-023-05989-3
pii: 10.1007/s00417-023-05989-3
pmc: PMC10368577
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2421-2429Informations de copyright
© 2023. The Author(s).
Références
Androudi S, Dastiridou A, Pharmakakis N et al (2016) Guidelines for the management of wet age-related macular degeneration: recommendations from a panel of Greek experts. Adv Ther 33(5):715–726
doi: 10.1007/s12325-016-0332-7
pubmed: 27116423
pmcid: 4882369
Arditi A, Cagenello R (1993) On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci 34(1):120–129
pubmed: 8425819
Bennett SR, Folk JC, Blodi CF, Klugman M (1990) Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109(1):33–37
doi: 10.1016/S0002-9394(14)75575-8
pubmed: 2297030
Bopp S (2012) Subretinal hemorrhage. Natural course and staging. Ophthalmol Z Dtsch Ophthalmol Ges 109:635–643
Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–14
Brown DM, Kaiser PK, Michels M et. al. ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355, 1432–1444
Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65
doi: 10.1016/j.ophtha.2008.10.018
pubmed: 19118696
Brown DM, Campochiaro PA, Singh RPCRUISE, Investigators, et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124–1133
doi: 10.1016/j.ophtha.2010.02.022
pubmed: 20381871
Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437
doi: 10.1016/j.ajo.2012.09.026
pubmed: 23218699
Brown DM, Nguyen QD, Marcus DM, RIDE and RISE Research Group et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120(10):2013–2022
doi: 10.1016/j.ophtha.2013.02.034
pubmed: 23706949
Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044–2052
doi: 10.1016/j.ophtha.2015.06.017
pubmed: 26198808
Brunner E, Konietschke F, Pauly M, Puri ML (2017) Rank-based procedures in factorial designs: hypotheses about non-parametric treatment effects. J Royal Stat Soc: Ser B (Statistical Methodology) 79(5):1463–1485
doi: 10.1111/rssb.12222
Campochiaro PA, Heier JS, Feiner L et al (2010) BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117(6):1102–1112
doi: 10.1016/j.ophtha.2010.02.021
pubmed: 20398941
Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336
doi: 10.1016/j.ophtha.2015.09.035
pubmed: 26522708
Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e. V. (RG), Berufsverband der AugenärzteDeutschlands e. V. (BVA) (2020) Statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : status February 2020. Ophthalmologe 117:746–754
Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e. V. (RG), Berufsverband der AugenärzteDeutschlands e. V (2020) Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : situation August 2019. Ophthalmologe 117:218–247
Dugel PU, Koh A, Ogura Y et al (2019) HAWK and HARRIER Study Investigators. HAWK and HARRIER phase 3 multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72–84
doi: 10.1016/j.ophtha.2019.04.017
pubmed: 30986442
Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72–84
Dugel PU, Singh RP, Koh A et al (2020) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89–99
Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89–99
doi: 10.1016/j.ophtha.2020.06.028
pubmed: 32574761
Germany Ophthalmology Society, Retina Society, Professional Asociation of German Ophthalmologists (2012) Statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies. Ophthalmologe 109:818–831
Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548
doi: 10.1016/j.ophtha.2012.09.006
pubmed: 23084240
Heier JS, Clark WL, Boyer DS et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414–1420
doi: 10.1016/j.ophtha.2014.01.027
pubmed: 24679444
Heier JS, Korobelnik JF, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123(11):2376–2385
doi: 10.1016/j.ophtha.2016.07.032
pubmed: 27651226
Heier JS, Khanani AM, Quezada Ruiz C et al (2022) TENAYA and LUCERNE Investigators Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729–740
doi: 10.1016/S0140-6736(22)00010-1
pubmed: 35085502
Heimes B, Schick T, Brinkmann CK et al (2016) Design des ORCA-Moduls der OCEAN-Studie: evaluierung der SD-OCT-Befunderhebung in der täglichen Praxisroutine [Design of the ORCA module in the OCEAN study: evaluation of SD-OCT results in daily routine practice]. Ophthalmologe 113(7):570–580
doi: 10.1007/s00347-016-0224-x
pubmed: 26868827
Holz FG, Roider J, Ogura Y et al (2013) VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278–284
doi: 10.1136/bjophthalmol-2012-301504
pubmed: 23298885
Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–54
Korobelnik JF, Holz FG, Roider J et al (2013) GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208
doi: 10.1016/j.ophtha.2013.08.012
pubmed: 24084497
Lange C, Feltgen N, Junker B, et. al. (2009) Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 247:137–142
doi: 10.1007/s00417-008-0926-0
pubmed: 18766368
Loumann KL (2003) Visual acuity testing in diabetic subjects: the decimal progression chart versus the Freiburg visual acuity test. Graefes Arch Clin Exp Ophthalmol 241(8):615–618
doi: 10.1007/s00417-003-0707-8
Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 118(4):615–25
doi: 10.1016/j.ophtha.2011.01.031
pubmed: 21459215
Nguyen QD, Brown DM, Marcus DM et al (2012) RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801
doi: 10.1016/j.ophtha.2011.12.039
pubmed: 22330964
Ogura Y, Roider J, Korobelnik JF et al (2014) GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158(5):1032–8
doi: 10.1016/j.ajo.2014.07.027
pubmed: 25068637
Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit [A new reading chart for simultaneous determination of reading vision and reading speed]. Klin Monbl Augenheilkd 213(3):174–181
doi: 10.1055/s-2008-1034969
pubmed: 9793916
Riedl S, Vogl WD, Waldstein SM et al (2022) Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retina 6(4):291–297
doi: 10.1016/j.oret.2021.12.007
pubmed: 34922038
Rosenfeld PJ, Brown DM, Heier JS et al (2006) MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
doi: 10.1056/NEJMoa054481
pubmed: 17021318
Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144–67
Schulze-Bonsel K, Feltgen N, Burau H et al (2006) Visual Acuities “Hand Motion” and “Counting Fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci 47:1236
doi: 10.1167/iovs.05-0981
pubmed: 16505064
Take P, Dittmann CA, Mackerodt L et al (2021) Das modifizierte treat-and-extend-schema mit injektionsblöcken in der IVOM-therapie: retrospektive analyse aus der täglichen klinischen anwendung [The modified treat and extend scheme with injection blocks in intravitreal injection treatment : retrospective analysis from the routine clinical application]. Ophthalmologe 118(6):578–586
doi: 10.1007/s00347-020-01218-y
pubmed: 32894329
Wykoff CC, Abreu F, Adamis AP et al (2022) YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741–755
doi: 10.1016/S0140-6736(22)00018-6
pubmed: 35085503
Wolfram C, Pfeiffer N (2012)Weißbuch zur Situation der ophthalmologischen Versorgung in Deutschland,München
Ziemssen F, Eter N, Fauser S et al (2015) Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe 112(3):246–54